Epigenetic regulatory abnormalities play an important role in the occurrence and development of hematological malignant neoplasms. Enhancer of Zeste homolog (EZH)2 is one of the important members of the polycomb group (PcG), which regulates the transcription of target genes through the specific catalytic tri-methylation at lysine 27 of histone H3 (H3K27me3). EZH2 is consistently highly expressed in a variety of hematological malignant neoplasms, which is associated with neoplasms invasiveness and poor prognosis of patients. The effect of EZH2 gene mutation on H2K27me3 is quite different in different types of hematological malignant neoplasms. This article intends to surmmarize the research status of EZH2 in hematological malignant neoplasms on the relation between EZH2 and hematological malignant neoplasms, as well as the applications of relevant targeted drugs.
